![Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression]()
Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expressionLi, Yan; Yimamu, Maimaitili; Wang, Xiaomin; Zhang, Xiaoyan; Mao, Min; Fu, Ling; Aisimitula, Aihemaitijiang; Nie, Yuling; Huang, Qin · International Journal of Hematology · 2014